AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2023 Annual Meeting of Stockholders held on May 18, 2023. The registrant, Aytu BioPharma, Inc., is a Delaware corporation with its principal executive offices in Englewood, Colorado. The report details the outcomes of shareholder votes regarding board elections, equity plans, auditor ratification, and executive compensation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance events and voting results.
Material Changes and Voting Results
Of the 3,778,722 shares outstanding on the record date, 1,942,164 shares were present or represented at the meeting. The following matters were voted upon:
- Board of Directors Election: Five directors were elected. Significant broker non-votes (952,620) were recorded for each nominee.
- Joshua R. Disbrow: 673,707 For, 315,837 Withheld.
- John A. Donofrio, Jr.: 677,912 For, 311,632 Withheld.
- Carl C. Dockery: 678,532 For, 311,012 Withheld.
- Vivian H. Liu: 685,411 For, 304,133 Withheld.
- 2023 Equity Incentive Plan: Approved with 632,357 votes in favor, 352,359 against, and 4,828 abstentions. There were 952,620 broker non-votes.
- Auditor Ratification: Grant Thornton, LLC was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2023, with 1,754,922 votes in favor, 132,135 against, and 55,107 abstentions.
- Executive Compensation (Say-on-Pay): The advisory vote was approved with 587,253 votes in favor, 383,698 against, and 18,593 abstentions. There were 952,620 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (3,778,722) and the percentage of shares represented at the meeting (approximately 51.4%).
- Note the high volume of broker non-votes (952,620) on the director elections and equity plan, indicating a significant portion of shares held by brokers were not voted on these specific matters.
- Confirm the approval of the new 2023 Equity Incentive Plan, which may impact future dilution.
- Review the "Say-on-Pay" vote results, where the "For" votes (587,253) were lower than the "Against" votes (383,698) relative to the total votes cast, though the proposal still passed.